密苏里州的 Mosaic Life Care 停止承保 $4.2M 罕见病基因疗法，影响像 Reed 这样的家庭。 Missouri's Mosaic Life Care stops covering $4.2M gene therapies for rare diseases, affecting families like Reed's.
花费高达420万美元的基因疗法越来越多地用于稀有疾病,但许多雇主正在缩小覆盖面。 Gene therapies, costing up to $4.2 million, are increasingly used for rare diseases, but many employers are cutting coverage. 密苏里州的 Mosaic Life Care 最近停止支付此类治疗费用，这影响了像 Amanda Reed 这样的家庭，他们的双胞胎男孩需要 Zolgensma 来治疗脊髓性肌萎缩症。 Mosaic Life Care in Missouri recently stopped paying for such treatments, impacting families like Amanda Reed's, whose twin boys need Zolgensma for spinal muscular atrophy. 随着治疗费用在今后十年内预计将达到400亿美元,许多雇主将这些药物排除在外,给工人带来巨大的获取和负担能力挑战。 With rising therapy costs expected to reach $40 billion over the next decade, many employers are excluding these drugs, creating significant accessibility and affordability challenges for workers.